Provida Dha label

Provida Dha

Provida Dha Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

WARNING: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

OVERDOSE: Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Other symptoms include pallor and cyanosis, melena, shock, drowsiness and coma. The estimated overdose of orally ingested iron is 300-mg/kg body weight. When overdoses are ingested by children, severe reactions, including fatalities, have resulted.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

There is currently no usage information available for this product. We apologize for any inconvenience.

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Provida Dha Manufacturers

  • Us Pharmaceutical Corporation
    Provida Dha | Us Pharmaceutical Corporation
    No Recall

    Provida Dha | Us Pharmaceutical Corporation

    Provida Dha | Us Pharmaceutical Corporation

    DOSAGE AND ADMINISTRATION: Adults (persons over 12 years of age), one (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.

    HOW SUPPLIED: ProvidaTM DHA are Swedish orange opaque capsules printed with “US” logo and “P DHA” in white. Child resistant bottles of 30 capsules NDC# 52747-503-30.

    Consult package literature for full prescription information. You should contact your healthcare provider for medical advice about adverse events. To report a serious adverse event, contact US Pharmaceutical Corporation, P.O. Box 360465, Decatur, GA 30036. Marketed by US Pharmaceutical Corporation. Manufactured with L-Vcaps® Plus capsule shells.

    Manufactured in FDA registered facility in the USA.

    Patent Numbers: USA: 6,797,266; 5,626,883; Mexico MX/a/2008/004461; Singapore: 20082623-9 and other countries.

    Vcaps® and the L-Vcaps® Plus Logo are trademarks used under license.